Researchers from the National Autonomous University of Mexico (UNAM) obtained the patent for a chemical formulation that protects the liver of patients infected with the HIV virus and helps to regenerate it.
The doctor Rolando Hernández Muñoz and chemist Armando Butanda Ochoa, both researchers from the Institute of Cellular Physiology (IFC), combined concentrations of Zidovudine (AZT) with adenosine (ADO), a compound that protects the liver against damage caused by cirrhosis and other hepatic diseases.
In addition, the researchers revealed that during their experimental work they were able to demonstrate that the combination of both substances can return the liver’s regenerative capacity to its normal levels.
The academics of the UNAM said that, although antiretrovirals containing AZT are efficient in the treatment of HIV/AIDS, patients suffer serious side effects.
Especially because they alter the generation of energy, they produce weakness and promote the accumulation of lipids, which produces fatty liver and also diminish the regeneration capacity of the liver tissue.
This is a therapeutic option to protect patients from the collateral damage caused by antiretroviral drugs, the researchers said.
A pharmaceutical formulation combining the treatment of antiretrovirals such as AZT, together with the ADO molecule, or a derivative of it, can be made to treat patients who are not treated before, while protect their liver, said Hernández.
Although the scientists obtained the patent, they explained that the medication is still in development process, for which they need to start a protocol in human patients and the support of a health institution.